No patients on soli have generated C. Diff. Moxi they have. So you don't know why? TSRX I got in cheaply for buyout. You still didn't answer question of which company was selling $50 million flop antibiotic. BTW I made money on OPTR PDUFA.
Good point. Soli stops C Diff, thats why its not being seen in patients on soli. I posted article details above.
Soli stops C. Diff. Jeez, for a pharma veteran you need to back up your statements with facts as to why soli doesn't spawn C. Diff.. Learn to use literature to figure out that your statement is incorrect, before spouting off. "CEM-101 displayed a MIC50 of 0.12 µg/mL against C. difficile and 0.06 µg/mL against other Clostridia species."
Source: Progress in the Discovery of Treatments for C. difficile Infection: A Clinical and Medicinal Chemistry Review. Author(s): Lissa S. Tsutsumi, Yaw B. Owusu, Julian G. Hurdle and Dianqing Sun
Curr Top Med Chem. 2014; 14(1): 152–175.
All right, I want to know all these companies that flopped with under $50 million in sales. I have been in pharma industry for a long time PhD, so if you would kindly list these antibiotics companies that flopped, I would appreciate. I have been in CEMP since $9's. DRTX had a long acting vanco, company bought out after approval. TSRX had a better Zyvox, bought by CBST along with OPTR. CBST bought for $8 billion by MRK. So according to you for CBST why wasn't some big pharma all over them when their drugs were in Phase 3? CBST had only $1 billion in sales when purchased by MRK. There is a dearth in antibiotic development pipeline, GAIN Act is helping, and CEMP will go higher in spite of your not agreeing with what it might be worth.
Read this from my other post: Btechg wrote this I copied it for you: "GB and Australia just about banned fluouroquinolones because of side effects. If Europe is begging for soli it must be a big deal. These soli trials were not done in these countries because it was unethical in their eyes. Bye Bye Moxi."
Europe doesn't pay for many drugs, but they want soli, listen to cc. Also Japan progressing.
still bung, IV should give tighter results and soli is being given for 7 days in this trial vs. 5 days in oral. Moxi given for 7 days in both trials.
She also said in EU they want to stay in hospital 7 days because it is better than going home with better food and care. I like your way of thinking, still they measure early clinical response at 72 hours in all in intent to treat as primary outcome.
IV is easier to meet than oral due to 100% bioavailability of IV admin, and this trial is for 7 days of soli vs 7 days moxi. in oral trial 5 days of soli dosing plus 2 days placebo vs 7 days moxi. go look at clinical trials gov
What is the problem why so hard to understand?
They converted the $65 million convertible, apparently from filings. Those shares were already in diluted share count. The new convertible are at $11.47 and only 4% interest.
This is the biggest macrolide antibiotic in recent years, even giving to Peds. NDA's to be filed in US in not too long. EU after that (they want this drug badly), Japan progressing also. NASH also a big need for that. $100 to even begin buyout talks would seem reasonable. Each month getting closer to big payday. IF Fools underprice it then let them leave.
Sentiment: Strong Buy